Introduction
============

According to the World Health Organization, the number of newly diagnosed colorectal cancer (CRC) cases will increase by 77% and the number of deaths by 80% by 2030 ([@b1-mco-0-0-2002],[@b2-mco-0-0-2002]). The expected increase in CRC will mainly occur in less developed countries,due to the development of a lifestyle closed to Western countries ([@b3-mco-0-0-2002]).

The neoplastic transformation time of CRC is \~10-15 years ([@b6-mco-0-0-2002]), and the 5 year survival following treatment 50-60% ([@b10-mco-0-0-2002],[@b11-mco-0-0-2002]). Reliable diagnostic, prognostic and predictive biomarkers are required ([@b12-mco-0-0-2002]). At present, the most accepted tests for CRC are fecal occult blood test, colonoscopy and sigmoidoscopy ([@b13-mco-0-0-2002]). Tumor node metastasis (TNM) staging and carcinoembryonic antigen level are also used. However, most of these tests have been reported to be too insensitive for accurate individual prognosis ([@b14-mco-0-0-2002],[@b15-mco-0-0-2002]). Tumor biomarkers with a high sensitivity and specificity are required. In this meta-analysis, the use of serum thymidine kinase 1 (STK1p) concentration for prognosis and treatment monitoring in CRC patients is discussed.

STK1p has been proven useful for predicting recurrence and survival in many types of human cancer ([@b16-mco-0-0-2002],[@b17-mco-0-0-2002]). TK1 is a kinase enzyme that converts deoxythymidine to deoxythymidine monophosphate and is involved in the synthesis of DNA, and thus related to cell growth rate (proliferation). The new-generation STK1p concentration assay shows an area under the curve (AUC) value of 0.96([@b18-mco-0-0-2002]), and is a more reliable assay than the serum TK activity ([@b19-mco-0-0-2002],[@b20-mco-0-0-2002]) and serum TK1 sandwich ELISA ([@b21-mco-0-0-2002]) assays. Low STK1p values are associated with a better prognosis ([@b16-mco-0-0-2002],[@b18-mco-0-0-2002],[@b22-mco-0-0-2002]). The STK1p marker is an independent prognostic factor for survival in CRC patients (n=504) ([@b28-mco-0-0-2002]). STK1p can distinguish malignant patients from benign tumor patients and healthy individuals, as well as predict the prognosis of survival and relapse. STK1p can also monitor the effect of the treatment, and is a useful biomarker for predicting the development of malignancies and discovering early-stage tumors ([@b18-mco-0-0-2002],[@b26-mco-0-0-2002],[@b28-mco-0-0-2002]).

A number of studies have focused on the use of STK1p in colorectal benign and malignant tumor patients, but most of them included a limited number of cases, thus reducing the reliability of the conclusions. Therefore, 20 colorectal studies were collected for the present meta-analysis, in order to obtain a sufficient number of cases. The results showed that STK1p values are significantly higher in CRC patients, as compared to heathy individuals or patients with benign tumors. STK1p was also used to monitor the effect of the surgery.

Materials and methods
=====================

### Literature search

A systematic literature search was conducted through the PubMed, Embase, CENTRAL, CNKI, Wanfang, VIP and SinoMed databases until August 31, 2019, using the following strategy keywords: ('thymidine kinase 1' or 'TK1') and ('colorectal' or 'colon' or 'rectal' or 'colorectum' or 'rectum') and ('cancer' or 'tumor' or 'carcinoma' or 'malignancy'). A more detailed description of the search strategy used is described in the beginning of the Results section. The literature search was restricted to human studies. There were no language restrictions.

The meta-analysis followed the PRISMA guidelines. The quality of the meta-analysis as a study was investigated using the Newcastle-Ottawa Scale Document Quality Assessment Scale (NOS). Only studies using the STK1p assay developed by us, tested in many clinical studies and statistically proved to be reliable were selected (summary in refs. [@b27-mco-0-0-2002],[@b28-mco-0-0-2002]), in order to guarantee the high quality of the STK1p results. Since no specific review protocol suitable for our meta-analysis was found, our own protocol was used.

All analyses were based on previously published studies, and therefore no ethical approval and patient consent were required.

### Inclusion and exclusion criteria Inclusion criteria

i\) STK1p as an endpoint; ii) STK1p was measured by the kit developed by SSTK Ltd; iii) patients with adenomatous polyps were identified by clinical endoscopy and pathological diagnosis. Patients were identified by pathological diagnosis, classified as stage I-III and grade 1-3, and confirmed to have no residual tumor following surgery; iv) healthy individuals were used as the control group. Healthy people were defined as disease-free checked by different imaging, blood tests and other pathological methods.

### Exclusion criteria

i\) Insufficient data; ii) TK1 immunohistochemistry and TK1 activity; iii) Invalid research data, which included physiological stress responses such as immunological reaction, inflammation and activation of metabolic adenosine mediators. Oxidative stress was considered a surgical stress response, together with myocardial injury, sepsis, pulmonary edema, and kidney and liver failure, which could increase mortality; iv) Healthy people were excluded when containing diseases associated with tumors proliferation, such as precancerous (moderate/severe types of hyperplasia of breast, prostate, gastrointestinal, cervix, liver cirrhosis, refractory anemia). Also excluded were people with risk-diseases associated with tumors progression such as liver disease, moderate/severe fatty liver, high risk for hepatitis B, abnormal liver function, obesity and benign tumors (such as renal, thyroid); and any of the following conditions: severe cardiac disease; using any medication that could affect the STK1 levels such as exogenous hormone therapy; pregnancy; or acute illness such as inflammation/virus infection within 4 weeks.

### Literature screening and data extraction Primary screening

The title and abstract of literatures were carefully reviewed, and 10% of the excluded papers were randomly selected to check the concordance rate.

### Secondary screening

After checking the abstracts, the full text of the papers was re-evaluated, and it was decided whether these papers should be included to the study or not, according to the criteria. Authors 1, 2 and 3 screened papers independently and discussed to reach an agreement; when met with a disagreement, the papers were rechecked by authors 5 and 6.

The following data were extracted from each study: First author\'s name, publication year, title of publication, published journal, study population, number of samples, design type and results.

### Statistical analysis

RevMan 5.1 statistical software provided by Networks of Cochrane Review Groups and Stata 12.0 data analysis and statistical software were used ([@b29-mco-0-0-2002]). A heterogeneity test was performed at the beginning, and depending on the results, a fixed or random effects model was used. A fixed effects model with an I^2^ of \<50% or random effects model with an I^2^ of \>50% was used to calculate the weighted mean difference and 95% confidence interval. In addition, Funnel plot and Egger\'s linear regression test was used to assess literature bias. For the comparison of STK1p concentration among the different groups of controls and patients, one-way analysis of variance followed by a post hoc least significant difference test was performed. SPSS version 19 was utilized for statistical analysis (IBM Corp.). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Literature search and study characteristics

The healthy control group included individuals with no evidence of tumors. Data from patients with colorectal neoplastic (adenomatous) polyps were used in the meta-analysis. Adenomatous polyps are benign tumors that originate from the mucus-secreting colonic epithelial cells ([@b9-mco-0-0-2002]). Tumors from CRC patients pathologically identified as clinical I-III degree and grade G1-G3 were defined as malignant. We had no information on whether other types of tumors besides CRC were identified in the benign or malignant tumor groups.

As shown in [Fig. 1](#f1-mco-0-0-2002){ref-type="fig"}, a total of 314 publications were initially identified through a search of the Pubmed, Embase, CENTRAL, CNKI, Wanfang, VIP and SinoMed databases. A total 176 publications were removed due to duplications and 138 were kept. Next, 89 publications were excluded from the remaining articles following a screening of the titles and abstracts, due to being conference abstracts or focusing on unrelated topics. Therefore, 49 full-text articles were assessed for eligibility. Among them, 13 were excluded, since another STK1 method was used instead of the SSTK dot blot ECL assay, 7 because they used different endpoints, and 9 due to incomplete data. Finally, 20 studies were included in this meta-analysis ([@b30-mco-0-0-2002]).

The number of manuscripts, patients involved and the STK1p mean values in the control, benign and malignant tumor groups are shown in [Table I](#tI-mco-0-0-2002){ref-type="table"}. Detailed information on the number of cases, age distribution, type of CRC, clinical stages grades and just before start of the surgery and one month after surgery reported in the individual publications are presented in [Table II](#tII-mco-0-0-2002){ref-type="table"}.

A total of 1,836 CRC patients were included in the 20 publications, including 774 benign tumor patients and 1,701 healthy individuals. The majority of CRC patients were male with an age-distribution of 16-85 years and colon cancer clinical stage of III and grade low/medium/high. The expression of STK1p increased significantly in the following manner: Controls \< benign \< malign (P\<0.001). The quality of the meta-analysis as a study was checked by the NOS and was found to be high, with 19 publications meeting 8 of the requirements of NOS, and 1 publication meeting 6. The results are presented in [Table III](#tIII-mco-0-0-2002){ref-type="table"}.

### STK1p values in different populations

The STK1p values were significantly different between healthy individuals and benign tumor patients, healthy individuals and CRC patients, and benign tumor and CRC patients ([Table I](#tI-mco-0-0-2002){ref-type="table"}, [Fig. 2A](#f2-mco-0-0-2002){ref-type="fig"}). The number of publications involved among the healthy controls were 19, the benign 10 and the malignant 20, corresponding to 1,701, 774 and 1,836 persons, respectively. The STK1p values decreased significantly (40%) 1 month after surgery ([Fig. 2B](#f2-mco-0-0-2002){ref-type="fig"}).

### Meta-analysis statistical calculation

Significant values were calculated using statistical programs for meta-analysis (see Material and methods sections). The results for the different test groups are shown in [Figs. 3](#f3-mco-0-0-2002){ref-type="fig"} and 4. The statistical values were calculated between healthy individuals and benign tumor patients ([Fig. 3B](#f3-mco-0-0-2002){ref-type="fig"}), healthy individuals and CRC malignant tumor patients ([Fig. 3A](#f3-mco-0-0-2002){ref-type="fig"}), benign and malignant tumor patients ([Fig. 3C](#f3-mco-0-0-2002){ref-type="fig"}), and before and after surgery ([Fig. 3D](#f3-mco-0-0-2002){ref-type="fig"}).

### STK1p of healthy individuals compared to benign tumor patients

In this statistical calculation 1,052 healthy individuals and 671 benign tumor patients from 9 studies were used. Based on a random effects model, the heterogeneity test showed that the STK1p value in healthy individuals was significantly lower than that in benign tumor patients ([Fig. 3B](#f3-mco-0-0-2002){ref-type="fig"}).

### STK1p of healthy individuals compared to CRC patients

Of the 20 publications received, 19 were used in this comparison, including 1,701 healthy individuals and 1,703 patients with CRC ([Fig. 3A](#f3-mco-0-0-2002){ref-type="fig"}). A heterogeneity test based on the random effects model showed that the STK1p value in CRC patients was statistically higher than that in healthy individuals.

### STK1p in benign tumor patients compared to CRC patients

Out of the 20 publications, 10 included data regarding STK1p in benign tumors and CRC ([Fig. 3C](#f3-mco-0-0-2002){ref-type="fig"}). There was a total of 774 cases in the benign tumor group and 904 in the CRC group. A heterogeneity test based on the random effects model showed that the STK1p values were significantly higher in CRC patients, as compared to benign tumor patients.

### STK1p level before and after surgery

All 20 publications included data regarding the STK1p level before and 1 month after surgery. A heterogeneity test, based on the random effects model, showed a significant decrease by 40% 1 month after surgery ([Fig. 3D](#f3-mco-0-0-2002){ref-type="fig"}).

### Sensitivity analysis

Sensitivity analysis was conducted to evaluate the effect of excluding any individual study. By excluding 1 article at a time in turn, the summary results of the remaining literatures did not substantially change ([Fig. 4A](#f4-mco-0-0-2002){ref-type="fig"}).

### Publication bias

Begg\'s Funnel-plot ([Fig. 4B](#f4-mco-0-0-2002){ref-type="fig"}) and Egger\' test ([Table IV](#tIV-mco-0-0-2002){ref-type="table"}) were used to examine the potential publication bias. There was no evidence of bias between the healthy individuals and the benign tumor group, healthy individuals and the malignant group, the benign and malignant tumor groups, or the before and after treatment groups. The Egger\'s test showed that the possibility of potential bias from each comparison analysis was very low (all P\>0.05; [Table IV](#tIV-mco-0-0-2002){ref-type="table"}). Based on these results, no significant publication bias was identified in this meta-analysis.

Discussion
==========

Meta-analysis is a statistical analysis that combines the results of multiple studies ([@b50-mco-0-0-2002]). In the present study, a meta-analysis was performed according to the aforementioned inclusion and exclusion criteria. No bias was found. We also found that STK1p was able to distinguish between healthy individuals and benign tumor patients, as well as between healthy/benign tumor and malignant tumor patients. STK1p also monitored the results of the surgery. Thus, STK1p is a reliable biomarker for the prognosis of benign tumor and CRC patients, and a useful follow-up tool for surgery.

The STK1p was determined by an assay with a high sensitivity (0.80) and specificity (0.99), and an AUC value of 0.96. This assay is the most sensitive assay for TK1 in the serum on the market today ([@b16-mco-0-0-2002]). The mean value of STK1p in the benign tumor patients was 1.64-fold higher than that in healthy individuals, but significantly lower than that in CRC patients (1.60-fold). Although the mean STK1p value in benign tumor patients was higher than that in healthy individuals, there was a deviation, with both low and high individual STK1p values. The benign tumor patients with higher STK1p values (\>2.0 pM) may be in a higher risk of developing malignancies than benign tumor patients with low STK1p values (\<2.0 pM). Based on a health screening study (n=35,365) ([@b18-mco-0-0-2002]), where patients with a STK1p value of \>2.0 pM were found to have a 3-5 times higher risk to develop a malignancy, we concluded that the risk for developing colorectal malignancies from a benign colorectal tumor should be higher in benign tumor patients with an STK1p value of \>2.0 pM. On the other hand, benign tumor patients with STK1p values of \<2.0 pM should have a low risk of developing CRC. STK1p was also found to have a prognostic potential in a randomised clinical trial that included patients with CRC (n=504) ([@b28-mco-0-0-2002]). Patients were followed up for 3-8 years. STK1p was compared with pathological stage and grade, lymph node metastasis, gender and age in relation to survival. A significantly worse survival was found among patients with high STK1p values (\>0.9 pM), as compared to patients with low STK1p values (≤0.9 pM) (P\<0.0001). Cox regression analysis demonstrated that STK1p, clinical stage and lymph node metastasis were independent prognostic factors, but Dukes\' stage (P=0.633), sex (P=0.976) and age (P=0.520) were not.

In the present meta-analysis, the cut-off STK1p value was set to 0.9 pM, based on receiver operating characteristic statistical analysis. It is important to understand that the cut-off value of STK1p may differ depending on the type of tumor and how the measurement of STK1p was performed (healthy screening, clinical trials, etc.).

CRC is a heterogeneous disease, with most cases originating from polyp precursors. Different clinical stages and pathological grades of CRC can lead to heterogeneity.

CRC, a complex disease, is caused by both genetic and environmental factors. Certain studies have shown that inherited genetic factors account for \~35% of the disease etiology ([@b53-mco-0-0-2002],[@b54-mco-0-0-2002]). It has been suggested that there may be two distinct categories of cancer: Right- and left-sided colon cancers that arise proximally or distally to the splenic flexure, respectively ([@b55-mco-0-0-2002]). A meta-analysis on vitamin E concentration in the serum suggested that serum vitamin E concentration was lower in patients with CRC than in healthy controls. Reduced serum vitamin E levels may therefore be a risk factor for CRC. However, prospective cohort studies are still required to assess the risk of serum vitamin E on CRC in the future ([@b56-mco-0-0-2002]). Although the original Dukes staging system has been modified several times, the extent of cancer invasion through the bowel wall and that of regional lymph node invasion is still the mainstay of TNM staging for CRC. A 17,641 patient-cohort study demonstrated that right- and left-sided colon carcinoma (CC) are significantly different in terms of epidemiological, clinical and histological parameters. Right-sided CC has been found to have a worse prognosis. These discrepancies may be due to genetic differences that determine distinct carcinogenesis and biological behaviour ([@b57-mco-0-0-2002]). There was no significant difference in recurrence rates between right- and left-sided CC and rectum carcinoma (RC), but the right-sided CC had a worse prognosis than left-sided CC and RC, possibly due to more advanced staging and fewer curative resections ([@b58-mco-0-0-2002]). Another study demonstrated that the patients with stage I right-sided CC had a significantly better 5 year disease free survival rate than those with left-sided CC; however, no significant difference was observed in the distribution of the first patients with recurrence ([@b59-mco-0-0-2002]). A retrospective design and single-institution study showed that patients with right-sided colon cancers presented with a significantly increased risk of locoregional recurrence. Right-sided location, female sex, T4 disease, lymph node metastasis, and perineural invasion are independent risk factors for the locoregional recurrence of colon cancer ([@b60-mco-0-0-2002]). Qin *et al* ([@b61-mco-0-0-2002]) found that right- and left-sided colon cancer had significantly different clinicopathological characteristics. Right-sided colon cancer had a higher incidence of recurrence than left-sided colon cancer. Patients with stage III right-sided colon cancer had a worse prognosis than those with stage III left-sided colon cancer. In addition, CRC results may vary from region to region, resulting in heterogeneity, depending on patients\' genetic characteristics and living conditions.

With regard to the heterogeneity in the STK1 results, in a preliminary CRC study on 492 patients (Prof. Desong Wan, Sun Yet-Sen University Cancer Centre, China) no significant difference (P≈0.628-0.645) was found in the STK1 values between right-(n=91) and left-(n=124) side colon cancer, and rectum (n=277). The STK1p value of right colon, left colon and rectum was 1.8±1.8, 1.9±1.8 and 1.9±1.8 pM, respectively. STK1p is therefore useful for assessing the proliferation rate in CRC serum samples.

Monitoring the response to treatment is important. Previous studies have shown that STK1p can be used not only to predict prognosis, relapse and survival, but also to monitor tumor treatment ([@b28-mco-0-0-2002]). In this meta-analysis, the half-life time of STK1p following surgery was found to be \~1 month, which is the half-life time identified following surgery in patients with lung cancer ([@b26-mco-0-0-2002]) and gastric carcinoma ([@b62-mco-0-0-2002]). In the case of gastric carcinoma, the STK1p values were significantly reduced to 52.7% 35 days after open surgery (P=0.0106). On the contrary, in the patients with distant metastases, the STK1p value increased to 173% at 35 days post-operatively. There was no significantly difference in TK activity. Similar results were also found in breast cancer ([@b20-mco-0-0-2002]). However, in the case of minimally invasive surgery, the half-life time of STK1p in patients with bladder carcinoma was only 1 week ([@b63-mco-0-0-2002]).

It is recommend that STK1p is combined with other tools to evaluate the treatment effect on patients with CRC. This will help individual treatment planning. The following parameters in combination with STK1p should be considered when designing a CRC study: i) CRC is a heterogeneous disease ([@b63-mco-0-0-2002]), the majority of which is developed from polyp precursors. Therefore, a complete study should use tools useful for the early detection, diagnosis, prognosis and management of CRC development from benign tumors; ii) Since CC and RC are two different types of malignancy ([@b64-mco-0-0-2002]), they should be evaluated separately; the same goes for right- and left-sided CC and RC; iii) While monitoring the effect of the treatment, the STK1p levels may change depending on clinical stage/grade and tumor type on an individual bases; iv) Since CRC results may differ between living area, depending on the genetic properties and living conditions of the patients, studies should include data from different health centres and oncology hospitals.

In summary, STK1p could potentially be used for the early detection of benign lesions to prevent their future development into colorectal malignancies, as well as for individual clinical dynamic monitoring of the results of surgery in patients with CRC. The combination of STK1p with colorectal imaging tools after treatment can provide a precise evaluation of the results of the therapy. Together with the use of colorectal-related biomarkers, tumor stage and grade for predicting the risk of relapse, STK1p can help doctors develope more accurate, individualized and rational treatment plans for patients.
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![Flow diagram of the literature search and study selection process.](mco-12-05-0440-g00){#f1-mco-0-0-2002}

![STK1p levels. (A) STK1p levels in healthy controls, benign patients and patients with malignant colorectal cancer patients. (B) STK1p levels in patients with malignant colorectal cancer before and after treatment. Data are presented as the mean ± standard deviation and significant values were determined using a t-test. STK1p, serum thymidine kinase 1.](mco-12-05-0440-g01){#f2-mco-0-0-2002}

![Forest plots for correlation analysis. Forest plots were assessed between (A) healthy controls vs. malignant patients, (B) healthy controls vs. CRC benign patients, (C) benign patients vs. CRC malignant patients and (D) before vs. after surgery. Black diamonds indicate the mean value. CRC, colorectal cancer; SD, standard deviation; CI, confidence interval; IV, inverse variation.](mco-12-05-0440-g02){#f3-mco-0-0-2002}

![Study sensitivity analyses and the evaluation of mean differences. Evaluations were performed between (A) healthy control group and the colorectal malignancy group, (B) the benign disease and the colorectal malignancy group and (C) between the results obtained before and after surgery in the colorectal cancer group.](mco-12-05-0440-g03){#f4-mco-0-0-2002}

###### 

No of publications in the group of controls, benign and malignant persons, no of samples and STK1p mean values in the various groups included in the present study.

  Variables           Control                                                 Benign                                                   Malignant
  ------------------- ------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Publications (n)    19                                                      10                                                       20
  Samples (n)         1,701                                                   774                                                      1,836
  STK1p (mean ± SD)   0.88±0.50                                               1.30±0.84                                                3.14±2.55
  P-value             0.00078^[a](#tfn1-mco-0-0-2002){ref-type="table-fn"}^   \<0.0001^[b](#tfn1-mco-0-0-2002){ref-type="table-fn"}^   \<0.0001^[c](#tfn1-mco-0-0-2002){ref-type="table-fn"}^

P-values corresponding to the comparison of STK1p values between groups.

^a^Control vs. benigh group,

^b^benigh vs. malignant group and

^c^malignant vs. control group. SD, standard deviation; STK1p serum thymidine kinase 1.

###### 

Summary of the clinical data included in each selected publication.

                                                                                                           Clinical stage (n)   Pathological grading (n)   CRC type   Surgery                               
  -------------------------------------------- ------------- ------- ------- ------- ------- ----- ------- -------------------- -------------------------- ---------- --------- ----- ------- ----- ------- -------
  An *et al* ([@b36-mco-0-0-2002]), 2016       Southwest     33              45      45            31-76                                                   45                         24      21    13      13
  Huo *et al* ([@b41-mco-0-0-2002]), 2015      East China    32      35      76      51      25    36-83                                                   76                         76                     
  Li ([@b46-mco-0-0-2002]), 2012               Southwest     120     100     120     78      42    31-80                                                   120                        60      60    120     120
  Li and Wang ([@b49-mco-0-0-2002]), 2009      East China    48      45      108     79      29    31-78                                                   108                                108            
  Liu *et al* ([@b40-mco-0-0-2002]), 2015      South China   600     137     65      65            22-67                                                   65                         65                     
  Lu *et al* ([@b44-mco-0-0-2002]), 2014       South China   40      61      77      43      34    38-88                                                   77                         38      39             
  Shen *et al* ([@b47-mco-0-0-2002]), 2011     East China    60      50      43      28      15    30-79                                                   43                         21      22    43      43
  Tian *et al* ([@b48-mco-0-0-2002]), 2010     East China    33              66      45      21    25-72                                                   66                         66            66      66
  Xia *et al* ([@b39-mco-0-0-2002]), 2015      East China    41              61      33      28    23-85                                                   61         43        18    61            16      16
  Qi *et al* ([@b45-mco-0-0-2002]), 2013       East China    45              104     104           32-81                                                   104                        52      52             
  Zeng and Zhang ([@b38-mco-0-0-2002]), 2015   East China            103     133     77      56    32-84                                                   133                        133                    
  Zhang *et al* ([@b42-mco-0-0-2002]), 2015    Huazhong      40      36      150     88      62    30-78                                                   150                        150           150     150
  Zhang *et al* ([@b43-mco-0-0-2002]), 2014    East China    161             64      64            35-84                                                   64                         35      29             
  Zhu *et al* ([@b35-mco-0-0-2002]), 2017      Huazhong      52      162     82      49      33    36-68   17                                              65         34        48            82             
  Zhu *et al* ([@b37-mco-0-0-2002]), 2015      East China    67              33      33            16-85   7                    8                          18                                 33    33      33
  Fan *et al* ([@b30-mco-0-0-2002]), 2019      Northwest     60      45      50      23      27    60-70                                                   50         31        19    50                     
  Jiang *et al* ([@b32-mco-0-0-2002]), 2018    East China    70              71      50      21    32-82   9                    26                         36         18        53    22      49             
  Weng ([@b31-mco-0-0-2002]), 2018             South China   64              64      36      28    42-73   15                   29                         20                                 64             
  Sun *et al* ([@b33-mco-0-0-2002]), 2018      Northeast     60              80      50      30    24-80                                                   80         54        26    80                     
  Ning *et al* ([@b34-mco-0-0-2002]), 2018     South China   75              344     344                   132                                             212                        177     167            
  Total number                                               1,701   774     1,836   1,385   451           180                  63                         1,593      180       164   1,110   726   441     441
  Age distribution                                           16-85   35-84                         23-85                                                                                            30-85   30-85

CRC, colorectal cancer; M, male; F, female; diff., differentiation.

###### 

Literature quality evaluation by Newcastle-Ottawa Scale Document Quality Assessment Scale (NOS).

  Author/(Ref), year                           Is the definition adequate?   Representativeness of cases   Section selection of controls   Definition of controls   Comparability of cases and controls on the basis of design and analysis   Ascertainment of exposure   Exposure same method of ascertainment for cases and controls   Non-response rate
  -------------------------------------------- ----------------------------- ----------------------------- ------------------------------- ------------------------ ------------------------------------------------------------------------- --------------------------- -------------------------------------------------------------- -------------------
  An *et al* ([@b36-mco-0-0-2002]), 2016       ^\*^                          ^\*^                          ^\*^                            ^\*^                     ^\*\*^                                                                    ^\*^                        ^\*^                                                           ^\*^
  Huo *et al* ([@b41-mco-0-0-2002]), 2015      ^\*^                          ^\*^                          ^\*^                            ^\*^                     ^\*\*^                                                                    ^\*^                        ^\*^                                                           ^\*^
  Li ([@b46-mco-0-0-2002]), 2012               ^\*^                          ^\*^                          ^\*^                            ^\*^                     ^\*\*^                                                                    ^\*^                        ^\*^                                                           ^\*^
  Li and Wang ([@b49-mco-0-0-2002]), 2009      ^\*^                          ^\*^                          ^\*^                            ^\*^                     ^\*\*^                                                                    ^\*^                        ^\*^                                                           ^\*^
  Liu *et al* ([@b40-mco-0-0-2002]), 2015      ^\*^                          ^\*^                          ^\*^                            ^\*^                     ^\*\*^                                                                    ^\*^                        ^\*^                                                           ^\*^
  Lu *et al* ([@b44-mco-0-0-2002]), 2014       ^\*^                          ^\*^                          ^\*^                            ^\*^                     ^\*\*^                                                                    ^\*^                        ^\*^                                                           ^\*^
  Shen *et al* ([@b47-mco-0-0-2002]), 2011     ^\*^                          ^\*^                          ^\*^                            ^\*^                     ^\*\*^                                                                    ^\*^                        ^\*^                                                           ^\*^
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###### 

Egger\'s linear regression test for the assessment of publication bias.

  Standard effect              Coefficient   Standard error   T value   p\>\|t\|   95% CI
  ---------------------------- ------------- ---------------- --------- ---------- -------------------------
  Control vs. benign                                                                
       Slope                   -0.8601885    0.2631424        -3.27     0.014      -1.482421 to -0.2379556
       Bias                    4.134483      2.616981         1.58      0.158      -2.053694 to 10.32266
  Control vs. malignant                                                             
       Slope                   -2.533914     0.249529         -10.15    0.000      -3.060375 to -2.007454
       Bias                    1.303459      2.242794         0.58      0.569      -3.428422 to 6.03534
  Benign vs. malignant                                                              
       Slope                   -2.50849      0.6528756        -3.84     0.005      -4.014024 to -1.002956
       Bias                    5.555459      4.287575         1.30      0.231      -4.331706 to 15.44262
  Before vs. after treatment                                                        
       Slope                   1.414582      0.2186961        6.47      0.001      0.8524054 to 1.976758
       Bias                    -0.6030739    1.460007         -0.34     0.744      -4.256143 to 3.249995

CI, confidence interval.

[^1]: ^\*^Contributed equally
